Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project - Aix-Marseille Université Access content directly
Journal Articles Lung Cancer Year : 2020

Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project

Roger Lacave
  • Function : Author
Jacques Cadranel
  • Function : Author
  • PersonId : 901162

Abstract

T790M mutations inEGFR-mutated non-small cell lung cancer (NSCLC) account for nearly 50% of acquired resistance mechanisms to EGFR-TKIs. Earlier studies suggested that tumor T790M could also be detected in TKI-naïve EGFR-mutated NSCLC. The aim of the study is to assess the prevalence and clinical significance of quantification of tumor pre-treatment T790M subclones.
Fichier principal
Vignette du fichier
S0169500219306944.pdf (745 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-02483277 , version 1 (21-07-2022)

Licence

Attribution - NonCommercial

Identifiers

Cite

Michèle Beau-Faller, Erwan Pencreach, Charlotte Leduc, Hélène Blons, Jean-Philippe Merlio, et al.. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project. Lung Cancer, 2020, 140, pp.19-26. ⟨10.1016/j.lungcan.2019.10.013⟩. ⟨hal-02483277⟩
128 View
46 Download

Altmetric

Share

Gmail Facebook X LinkedIn More